Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Submitted by admin on February 22, 2019 - 10:04am
Source: 
Pharmaceutical Business Review
News Tags: 
Amgen
heart failure with reduced ejection fraction
Omecamtiv Mecarbil
Cytokinetics
Servier
Headline: 
Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure
snippet: 

Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv

Do Not Allow Advertisers to Use My Personal information